DVA

Business profile & competitive position

DaVita Inc. is classified in the Healthcare sector under the Medical - Care Facilities industry, and its core business is kidney dialysis. As of December 31, 2025, the company operated 2,657 outpatient U.S. dialysis centers serving roughly 200,500 patients, plus a laboratory and ancillary-services footprint. Internationally, DaVita ran 585 outpatient dialysis centers across 14 countries serving approximately 94,500 patients. That scale makes it one of the largest dedicated dialysis providers in the United States, with U.S. dialysis alone representing about 86% of consolidated revenues. Quality-program credentials are notable: DaVita has led CMS’s Quality Incentive Program for 11 of the most recently reported years and the Five-Star Quality Rating System for 10 of the most recently reported years. Those awards point to operational consistency, though they do not by themselves guarantee pricing power.

The financial returns tell a more nuanced story. The company posts a positive net margin of 6.0%, which is respectable for a service-heavy healthcare operator but not a sign of a wide, capital-light moat. Meanwhile, return on equity is deeply negative at -123.6%. A negative ROE on still-positive earnings implies the equity base has been eroded—commonly by share buybacks, accumulated deficits, or a debt-heavy capital structure—so the business is producing profits on a shrunken or negative book value. In practical terms, DaVita’s competitive edge looks like scale, payer contracting leverage, and network density rather than extraordinary margins or fortress balance-sheet returns.

Financial posture

DaVita carries an $11.4 billion market capitalization and trades at a trailing P/E of 15.3, which sits below the multiple many broad healthcare services names command. The beta is 0.87, indicating lower market sensitivity than the average stock. Net margin is 6.0%, and ROE is -123.6%. As of the current snapshot, the stock price was $178.1, the 50-day exponential moving average was $207.39, and the RSI was 25.1—technically oversold territory relative to the recent trend.

The combination of a positive 6.0% net margin with a -123.6% ROE is the key tension. Earnings exist, but they are not generated on a conventionally healthy equity base, so a 15.3 P/E by itself can be misleading. Investors typically need to pair that P/E with leverage, cash-flow, and debt metrics before drawing valuation conclusions. The low beta and care-facilities profile suggest defensive cash-flow characteristics, but the negative equity figure flags capital-structure risk.

Strategic priorities & outlook

DaVita’s most recent 10-K frames three operational priorities. The first is to “reimagine” kidney care so that it is more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. The second is to build integrated-care capabilities that coordinate patients across the renal continuum from chronic kidney disease to end-stage kidney disease to kidney transplant. The third is to support CMS’s Comprehensive Kidney Care Contracting model, which explicitly targets delaying disease progression, promoting home dialysis when appropriate, and incentivizing transplants.

These priorities matter because dialysis economics are evolving away from pure fee-for-service volume. Bundled payments, value-based care, and transplant/home-dialysis incentives can change revenue per treatment and patient mix. The 10-K also highlights a structural vulnerability: nearly all non-hospital dialysis profits come from commercial payors, even though Medicare covers the largest share of patients. That makes the commercial insurance rate environment a central variable. International expansion provides diversification—585 centers in 14 countries—but at roughly 14% of revenue it is still a sidelines story.

Macro & geopolitical exposure

As a Medical - Care Facilities operator focused on dialysis, DaVita is exposed to the broader healthcare reimbursement and regulatory cycle. Medicare and Medicaid payment rates, CMS rulemaking, and value-based contracting models directly affect pricing. Changes to the End-Stage Renal Disease payment bundle, add-on payments for oral drugs, or shifts in the Comprehensive Kidney Care Contracting model can move revenue and margins quickly. Labor is another industry-wide pressure point: dialysis centers require nurses, technicians, and dietitians, so wage inflation and staffing shortages can hit unit economics. Supply-chain exposure runs through dialyzers, concentrates, water-treatment systems, and other single-use medical supplies; tariffs or disruptions on imported devices would flow through costs. International operations introduce currency-translation and jurisdictional-regulatory risk. Finally, shifts in U.S. healthcare policy—whether toward tighter government budgets or expanded commercial coverage—can compress or widen the spread between government and private-pay reimbursement.

Recent developments

Recent headlines have been mixed. On August 15, 2026, defenseworld.net reported that Bank of America Corp DE cut its holdings in DaVita. On August 6, 2026, zacks.com asked whether DaVita was a good value stock right now. Then on August 5, 2026, zacks.com noted that DaVita stock was down in pre-market despite a Q2 earnings beat, with margins lower. That same day, zacks.com summarized the Q2 earnings call as centering on clinical-led volume growth.

The August 5 price action encapsulates the story: a quarterly beat did not prevent a sell-off because the market focused on margin compression and the forward outlook. In a business where commercial payor profits are scarce and quality metrics are strong, volume growth is welcome, but investors also want to see that volume translate into stable or expanding margins.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings expectations six times, a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day post-earnings move across those quarters is 6.36% to the upside. That sounds like a stock that rewards beats, but the underlying quarter-to-quarter dynamics are far messier.

The last four reports make the point. On August 4, 2026, DaVita reported EPS of $4.02 against an estimate of $3.88—a 3.6% positive surprise—but the stock fell 17.24% the next day and 21.78% over the following five sessions. On May 5, 2026, EPS of $2.87 beat the $2.41 estimate by 19.1%, and the stock surged 23.46% the next day and 27.7% over five days. On February 2, 2026, EPS of $3.40 beat the $3.24 estimate by 4.9%, driving gains of 21.17% the next day and 23.79% over five days. The outlier in the other direction was October 29, 2025, when EPS of $2.51 missed the $3.17 estimate by 20.8%, sending the stock down 6.17% the next day and 4.27% over five days.

The takeaway is that DaVita’s post-earnings reaction is highly asymmetric. A beat can produce either a large rally or a severe drawdown, and the August 2026 quarter shows that even a modest beat is no defense against a repricing on margins or guidance. The next earnings report is scheduled for October 28, 2026, after the close, with a consensus EPS estimate of $3.68.

For a more complete picture—especially around the latest institutional ownership shifts, sell-side ratings, and peer comparisons within dialysis and care facilities—investors should examine the full institutional verdict on the ticker page rather than relying on any single earnings snapshot.